ClinicalTrials.gg

Carcinoma, Renal Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,041 studies for Carcinoma, Renal Cell across more than 10 countries. 397 are recruiting or about to start. 1,438 of them are mainly about Carcinoma, Renal Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Clear-cell metastatic renal cell carcinoma too: 2,067 studies, 407 open.

ClinicalTrials.gov finds 2,518 studies for Carcinoma, Renal Cell. How that becomes 2,039 here

This page counts the studies the registry files under Carcinoma, Renal Cell, and those it files under no condition that list Carcinoma, Renal Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,518Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −26Filed under a narrower condition, counted on its own pageClear-cell metastatic renal cell carcinoma 26
  3. −35List Carcinoma, Renal Cell as a condition, but the registry did not file them under itMost often written as “Advanced Renal Cell Carcinoma” (8), “Renal Cell Cancer Metastatic” (6), and “Renal Cell Carcinoma Metastatic” (4). The registry filed them under other conditions only, most often Kidney Neoplasms (12) and Prostatic Neoplasms (6).
  4. −419Match it another way86 name it in the title, 3 in a keyword, and 330 by a synonym or other text the search reads.
  5. 2,038Counted here and found by its search73 of them list Carcinoma, Renal Cell in their own words; the registry filed them under no condition.
  6. +1
    Counted here, but its search does not find them
  7. 2,039The count on this page

Status

Completed
944
Recruiting
309
Terminated
289
Active, not recruiting
170
Status unknown
141
Not yet recruiting
81

Phase

Phase 2
861
Phase 1
626
Phase 3
130
Early Phase 1
33
Phase 4
26

Where

United States
1,142
China
234
France
201
United Kingdom
168
Spain
164
Canada
160

Who develops what

Add Carcinoma, Renal Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 56 programs from 40 companies, 36 with this as their studies’ main aim; 4 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Bristol-Myers Squibb, AstraZeneca and Beijing Biotech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
NivolumabRecent, repeated
Evidence
  • NCT07877194 · Summit Therapeutics · Phase 2 · live · comparator · “Nivolumab combined with Ipilimumab” · registered Sep 2026
  • NCT07494435 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Nivolumab (240 mg)” · registered Mar 2026
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT05678673 · Exelixis · Phase 3 · live · background · “Nivolumab” · registered Dec 2022
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)66 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT06716853 · genenta science · Phase 2 · background · “Pembrolizumab” · registered Nov 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT05805501 · Hoffmann-La Roche · Phase 2 · comparator · “Pembrolizumab” · registered Mar 2023
  • NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)66 studies
IpilimumabRecent, repeated
Evidence
  • NCT07877194 · Summit Therapeutics · Phase 2 · live · comparator · “Nivolumab combined with Ipilimumab” · registered Sep 2026
  • NCT07227415 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
  • NCT04203901 · CoImmune · Phase 2 · background · “Nivolumab+Ipilimumab” · registered Dec 2019
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)44 studies
AxitinibRecent, repeated
Evidence
  • NCT05805501 · Hoffmann-La Roche · Phase 2 · background · “Axitinib” · registered Mar 2023
  • NCT05522231 · HUTCHMED · Phase 3 · comparator · “axitinib / everolimus” · registered Aug 2022
  • NCT05256472 · Akeso · Phase 2 · background · “axitinib” · registered Jan 2022
  • NCT02667886 · X4 Pharmaceuticals · Phase 2 · background · “axitinib” · registered Jan 2016
  • NCT02639182 · Astellas Pharma Inc · Phase 2 · comparator · “Axitinib” · registered Dec 2015
Pfizer80% of its industry studiesUS: Pfizer (FDA 2012)EU: off-patent, 1 generic authorized33 studies
BevacizumabRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “bevacizumab” · registered Mar 2023
  • NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Apr 2019
  • NCT02187302 · Lumos Pharma, Inc. · Phase 2 · background · “Bevacizumab” · registered Jun 2014
  • NCT00719264 · Novartis · Phase 2 · background · “bevacizumab” · registered Jul 2008
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others22 studies
PaclitaxelRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT05824975 · GI Innovation, Inc. · Phase 2 · live · background · “paclitaxel” · registered Mar 2023
  • NCT04198766 · Inhibrx Biosciences, Inc · Phase 2 · live · background · “Paclitaxel 200mg/m2” · registered Dec 2019
  • NCT03693612 · GlaxoSmithKline · Phase 2 · comparator · “Paclitaxel” · registered Oct 2018
  • NCT02599324 · AbbVie · Phase 2 · background · “paclitaxel” · registered Nov 2015
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed22 studies
cabozantinibRecent, repeated
Evidence
  • NCT07293351 · Bristol-Myers Squibb · Phase 2 · live · background · “Cabozantinib” · registered Dec 2025
  • NCT06716853 · genenta science · Phase 2 · background · “Cabozantinib” · registered Nov 2024
  • NCT04586231 · Merck & Co., Inc · Phase 3 · live · comparator · “Cabozantinib” · registered Oct 2020
  • NCT04300140 · Aravive, Inc. · Phase 2 · background · “Cabozantinib (Cabo)” · registered Mar 2020
  • NCT03729245 · Nektar Therapeutics · Phase 3 · comparator · “cabozantinib” · registered Oct 2018
Exelixis64% of its industry studiesUS: Exelixis (FDA 2012)EU: Ipsen (EMA 2014)22 studies
atezolizumabRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
  • NCT06090318 · Rain Oncology Inc · Phase 2 · background · “Atezolizumab” · registered Nov 2022
  • NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Apr 2019
  • NCT03829501 · Sanofi · Phase 2 · background · “Atezolizumab” · registered Jan 2019
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies
casdatifanRecent, repeated
Evidence
  • NCT07293351 · Bristol-Myers Squibb · Phase 2 · live · background · “Casdatifan” · registered Dec 2025
  • NCT07227415 · Pfizer · Phase 2 · live · background · “Casdatifan” · registered Nov 2025
Arcus Biosciences, Inc.78% of its industry studies22 studies

22 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zanzalintinib☆ Track2 live phase-3 studies: NCT07620574, NCT05678673Exelixis
cabozantinibApproved: US 2012 · EU 2014☆ Track2 live phase-3 studies: NCT07620574, NCT03937219Exelixis
zanzalintinib☆ Track2 live phase-3 studies: NCT07489495, NCT07227402Merck & Co., Inc
Zirconium Zr 89 Girentuximab☆ Track1 live phase-3 study: NCT06750419Telix Pharmaceuticals Limited

The 4 in phase 3 with the nearest primary completion, of 56 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 15 Dec 2026 est.zanzalintinib · Exelixis · Phase 3 main aim+ Nivolumab vs Sunitinibstudied with NivolumabNCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma — primary endpoint: Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC) · 317 enrolled
  • 31 Dec 2026 est.IBR854 · Imbioray (Hangzhou) Biomedicine Co., Ltd. · Phase 2 main aimadded to pazopanibNCT07087158 A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma — primary endpoint: Progression-free Survival (PFS) · 30 enrolled
  • Feb 2027 est.GI-108 · GI Innovation, Inc. · Phase 2 named, not the main aimNCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors — primary endpoint: Incidence of Dose-Limiting Toxicities (DLTs) (Dose escalation phase) · 102 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Renal Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 65 open · Tyrosine kinase inhibitors (TKIs) 57 open · Angiogenesis inhibitors 4 open · mTOR inhibitors 4 open · Antimetabolites 4 open

Coming up

168studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger. 21 (7%) take children under 18. 0 (0%) are for women only and 2 (1%) for men only; 20 (6%) take healthy volunteers.

Recruiting studies that take each age, of 309
AgeWomenMen
1015 (5%)15 (5%)
18298 (96%)300 (97%)
30302 (98%)304 (98%)
40302 (98%)304 (98%)
50302 (98%)304 (98%)
65304 (98%)306 (99%)
75301 (97%)303 (98%)
85270 (87%)272 (88%)

Across all 2,041 studies, recruiting or not: 7% stop at 75 or younger and 2% at 65; 8% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Renal Cell studies take

Of 231 phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 59 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo32–73 · 220 studies49 mo32–63 · 138 studies54 mo31–76 · 82 studies
Phase 1/264 mo45–87 · 111 studies67 mo44–78 · 70 studies64 mo45–132 · 41 studies
Phase 259 mo33–94 · 231 studies33 mo24–52 · 47 studies67 mo41–98 · 184 studies
Phase 356 mo42–89 · 61 studies49 mo31–59 · 35 studies—
Interventional, no phase45 mo22–114 · 127 studies—51 mo24–114 · 120 studies
Observational50 mo33–94 · 139 studies48 mo36–91 · 42 studies51 mo26–241 · 97 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 2,041. Browse all 2,041 → or search them.